Search tips
Search criteria 


Logo of gutGutView this articleSubmit a manuscriptReceive email alertsContact usBMJ
Gut. 1996 November; 39(5): 649–653.
PMCID: PMC1383386

Marked increase in gastric acid secretory capacity after omeprazole treatment.


BACKGROUND: In contrast with the histamine2 (H2) blockers, proton pump inhibitors have not been shown to give rebound hypersecretion of acid. Taking into consideration the hyperplasia of the enterochromaffin-like (ECL) cell provoked by hypergastrinaemia secondary to profound acid inhibition and the central role of histamine from ECL cells in the regulation of acid secretion, the lack of any rebound acid hypersecretion after treatment with proton pump inhibitors has been questioned. AIMS: To reassess the effect of treatment with omeprazole on post-treatment acid secretion. METHODS AND PATIENTS: Basal and pentagastrin stimulated acid secretion were determined in nine patients with reflux oesophagitis before and 14 days after termination of a 90 day treatment period with the proton pump inhibitor omeprazole (40 mg daily). Basal gastrin release were determined before and during omeprazole treatment. Furthermore, biopsy samples from the oxyntic mucosa were taken before and at the end of the treatment period for chemical (histamine and chromogranin A (CgA)) evaluation of the ECL cell mass. RESULTS: A substantial increase in meal stimulated gastrin release during omeprazole treatment resulted in an increased ECL cell mass. Furthermore, CgA in serum increased during omeprazole treatment suggesting that serum CgA may be used as a test to evaluate ECL cell hyperplasia. A significant increase in basal and a marked (50%) and significant increase in pentagastrin stimulated acid secretion were found after treatment with omeprazole. CONCLUSIONS: Increased acid secretion after a conventional treatment period with a proton pump inhibitor is probably due to ECL cell hyperplasia and may have negative consequences for acid related diseases.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1002K), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Blair AJ, 3rd, Richardson CT, Walsh JH, Feldman M. Variable contribution of gastrin to gastric acid secretion after a meal in humans. Gastroenterology. 1987 Apr;92(4):944–949. [PubMed]
  • Sandvik AK, Waldum HL, Kleveland PM, Schulze Søgnen B. Gastrin produces an immediate and dose-dependent histamine release preceding acid secretion in the totally isolated, vascularly perfused rat stomach. Scand J Gastroenterol. 1987 Sep;22(7):803–808. [PubMed]
  • Waldum HL, Sandvik AK, Brenna E, Schulze Søgnen B. Radioimmunoassay of histamine. Scand J Gastroenterol Suppl. 1991;180:32–39. [PubMed]
  • Leth R, Olbe L, Haglund U. The pentagastrin-induced gastric acid response in humans. Scand J Gastroenterol. 1988 Mar;23(2):224–228. [PubMed]
  • Waldum HL, Sandvik AK, Brenna E, Petersen H. Gastrin-histamine sequence in the regulation of gastric acid secretion. Gut. 1991 Jun;32(6):698–701. [PMC free article] [PubMed]
  • Ryberg B, Tielemans Y, Axelson J, Carlsson E, Håkanson R, Mattson H, Sundler F, Willems G. Gastrin stimulates the self-replication rate of enterochromaffinlike cells in the rat stomach. Effects of omeprazole, ranitidine, and gastrin-17 in intact and antrectomized rats. Gastroenterology. 1990 Oct;99(4):935–942. [PubMed]
  • Brenna E, Waldum HL. Trophic effect of gastrin on the enterochromaffin like cells of the rat stomach: establishment of a dose response relationship. Gut. 1992 Oct;33(10):1303–1306. [PMC free article] [PubMed]
  • Waldum HL, Sandvik AK, Syversen U, Brenna E. The enterochromaffin-like (ECL) cell. Physiological and pathophysiological role. Acta Oncol. 1993;32(2):141–147. [PubMed]
  • Kleveland PM, Waldum HL, Larsson H. Gastric acid secretion in the totally isolated, vascularly perfused rat stomach. A selective muscarinic-1 agent does, whereas gastrin does not, augment maximal histamine-stimulated acid secretion. Scand J Gastroenterol. 1987 Aug;22(6):705–713. [PubMed]
  • Waldum HL, Sandvik AK. Histamine and the stomach. Scand J Gastroenterol. 1989 Mar;24(2):130–139. [PubMed]
  • Waldum HL, Lehy T, Brenna E, Sandvik AK, Petersen H, Søgnen BS, Bonfils S, Lewin MJ. Effect of the histamine-1 antagonist astemizole alone or with omeprazole on rat gastric mucosa. Scand J Gastroenterol. 1991 Jan;26(1):23–35. [PubMed]
  • Lamberts R, Creutzfeldt W, Stöckmann F, Jacubaschke U, Maas S, Brunner G. Long-term omeprazole treatment in man: effects on gastric endocrine cell populations. Digestion. 1988;39(2):126–135. [PubMed]
  • Klinkenberg-Knol EC, Festen HP, Jansen JB, Lamers CB, Nelis F, Snel P, Lückers A, Dekkers CP, Havu N, Meuwissen SG. Long-term treatment with omeprazole for refractory reflux esophagitis: efficacy and safety. Ann Intern Med. 1994 Aug 1;121(3):161–167. [PubMed]
  • Syversen U, Mignon M, Bonfils S, Kristensen A, Waldum HL. Chromogranin A and pancreastatin-like immunoreactivity in serum of gastrinoma patients. Acta Oncol. 1993;32(2):161–165. [PubMed]
  • Lorenz W. Histamine release in man. Agents Actions. 1975 Dec;5(5):402–416. [PubMed]
  • Morel AM, Delaage MA. Immunoanalysis of histamine through a novel chemical derivatization. J Allergy Clin Immunol. 1988 Oct;82(4):646–654. [PubMed]
  • Syversen U, Jacobsen MB, O'Connor DT, Rønning K, Waldum HL. Immunoassays for measurement of chromogranin A and pancreastatin-like immunoreactivity in humans: correspondence in patients with neuroendocrine neoplasia. Neuropeptides. 1994 Mar;26(3):201–206. [PubMed]
  • Carlsson E, Larsson H, Mattsson H, Ryberg B, Sundell G. Pharmacology and toxicology of omeprazole--with special reference to the effects on the gastric mucosa. Scand J Gastroenterol Suppl. 1986;118:31–38. [PubMed]
  • Merki HS, Wilder-Smith CH. Do continuous infusions of omeprazole and ranitidine retain their effect with prolonged dosing? Gastroenterology. 1994 Jan;106(1):60–64. [PubMed]
  • Fullarton GM, McLauchlan G, Macdonald A, Crean GP, McColl KE. Rebound nocturnal hypersecretion after four weeks treatment with an H2 receptor antagonist. Gut. 1989 Apr;30(4):449–454. [PMC free article] [PubMed]
  • Sharma BK, Walt RP, Pounder RE, Gomes MD, Wood EC, Logan LH. Optimal dose of oral omeprazole for maximal 24 hour decrease of intragastric acidity. Gut. 1984 Sep;25(9):957–964. [PMC free article] [PubMed]
  • Lind T, Cederberg C, Ekenved G, Haglund U, Olbe L. Effect of omeprazole--a gastric proton pump inhibitor--on pentagastrin stimulated acid secretion in man. Gut. 1983 Apr;24(4):270–276. [PMC free article] [PubMed]
  • Prewett EJ, Hudson M, Nwokolo CU, Sawyerr AM, Pounder RE. Nocturnal intragastric acidity during and after a period of dosing with either ranitidine or omeprazole. Gastroenterology. 1991 Apr;100(4):873–877. [PubMed]
  • Creutzfeldt W, Stöckmann F, Conlon JM, Fölsch UR, Bonatz G, Wülfrath M. Effect of short- and long-term feeding of omeprazole on rat gastric endocrine cells. Digestion. 1986;35 (Suppl 1):84–97. [PubMed]
  • Prewett EJ, Smith JT, Nwokolo CU, Hudson M, Sawyerr AM, Pounder RE. Eradication of Helicobacter pylori abolishes 24-hour hypergastrinaemia: a prospective study in healthy subjects. Aliment Pharmacol Ther. 1991 Jun;5(3):283–290. [PubMed]
  • Go VL, Hofmann AF, Summerskill WH. Simultaneous measurements of total pancreatic, biliary, and gastric outputs in man using a perfusion technique. Gastroenterology. 1970 Mar;58(3):321–328. [PubMed]
  • el-Omar E, Penman I, Dorrian CA, Ardill JE, McColl KE. Eradicating Helicobacter pylori infection lowers gastrin mediated acid secretion by two thirds in patients with duodenal ulcer. Gut. 1993 Aug;34(8):1060–1065. [PMC free article] [PubMed]
  • Waldum HL, Brenna E, Kleveland PM, Sandvik AK. Gastrin-physiological and pathophysiological role: clinical consequences. Dig Dis. 1995 Jan-Feb;13(1):25–38. [PubMed]
  • Tielemans Y, Axelson J, Sundler F, Willems G, Håkanson R. Serum gastrin concentration affects the self replication rate of the enterochromaffin like cells in the rat stomach. Gut. 1990 Mar;31(3):274–278. [PMC free article] [PubMed]
  • Chen D, Uribe A, Håkanson R, Sundler F. Somatostatin cells in the oxyntic mucosa of hypo- or hypergastrinemic rats. Scand J Gastroenterol. 1992 Jun;27(6):479–482. [PubMed]
  • Pisegna JR, Norton JA, Slimak GG, Metz DC, Maton PN, Gardner JD, Jensen RT. Effects of curative gastrinoma resection on gastric secretory function and antisecretory drug requirement in the Zollinger-Ellison syndrome. Gastroenterology. 1992 Mar;102(3):767–778. [PubMed]
  • Metz DC, Pisegna JR, Fishbeyn VA, Benya RV, Feigenbaum KM, Koviack PD, Jensen RT. Currently used doses of omeprazole in Zollinger-Ellison syndrome are too high. Gastroenterology. 1992 Nov;103(5):1498–1508. [PubMed]

Articles from Gut are provided here courtesy of BMJ Publishing Group